ISAD 2023 Gdańsk motto: Solidarity in AD
Keynote speakers
- Jiyoung AHN, Seoul (Republic of Korea)
- Martin BACHMANN, Bern (Switzerland)
- George du TOIT, London (UK)
- Ousmane FAYE, Bamako (Mali)
- Erika JENSEN-JAROLIM, Vienna (Austria)
- Christian VESTERGAARD, Aarhus (Denmark)
- Andreas WOLLENBERG, Munich (Germany)
- Alexander ZINK, Munich (Germany)
To attend virtually or to get all posters…
Please note all sessions will be based on Gdańsk time zone.
➜ Central European Summer Time (CEST) / Poland time (Warsaw) / UTC+2
Solidarity Day
|
||
|---|---|---|
| 08:00 |
Worldwide Solidarity in the Care of AD Patients
|
|
| 12:00 | 60 min Lunch break | |
| 13:00 |
Welcome addresses |
|
| 13:00 |
Welcome to GdańskMagdalena TRZECIAK, Gdańsk |
|
| 13:05 |
ISAD: past, present, futureAlain TAÏEB, Bordeaux |
|
| 13:20 | 1. | Initiatives at the international level Chairs: Magdalena TRZECIAK, Roberto TAKAOKA (01h30) |
| 13:20 | IL1 |
Keynote lecture: Atopic dermatitis and teledermatology in MaliOusmane FAYE, Bamako |
| 13:40 | IL2 |
Atopic dermatitis in ChinaLin MA, Beijing |
| 13:52 | IL3 |
Atopic dermatitis in AustraliaJohn C. SU, Melbourne |
| 14:04 | IL4 |
Phenotypes and endotypes of atopic dermatitis in ChileArturo BORZUTZKY, Santiago |
| 14:16 | IL5 |
Atopic dermatitis in QatarMartin STEINHOFF, Doha |
| 14:28 | IL6 |
Management of Atopic dermatitis in MadagascarFahafahantsoa RAPELANORO RABENJA, Antananarivo |
| 14:40 | IL7 |
Atopic dermatitis in PolandMagdalena TRZECIAK |
| 14:50 |
Q&A |
|
| 15:00 | 2. | A multispecialty approach Chairs: Roman NOWICKI, Peter SCHMID-GRENDELMEIER (01h30) |
| 15:00 | IL8 |
Keynote lecture: AD and food allergyGeorge du TOIT, London |
| 15:20 | IL9 |
Disease antagonisms in atopic dermatitis between comorbidity and co-protection – implications for therapyJohannes RING |
| 15:35 | IL10 |
AD and asthma. T2 siblings?Maciej KUPCZYK, Łódź |
| 15:50 | IL11 |
Microbiota modulation for AD: benefits or hype?Hanna SZAJEWSKA, Warsaw |
| 16:05 | IL12 |
Feeling well, being well – the brain-skin connectionWiesław CUBAŁA, Gdańsk |
| 16:20 |
Q&A |
|
| 16:30 | Poster session 1 + 30 min Coffee break [details] | |
| 17:00 | 3. | Accessibility to drugs in AD Moderators: José RUIZ-POSTIGO, Alain TAÏEB (01h00) |
Summary of the ISAD-WHO pre-meetingRoundtable format |
||
| 19:00 | Opening Ceremony / Welcome reception: Artus Court — ➜ Check details here | |
On the way to freedom?
|
||
| 08:30 | 4. | Mechanisms of disease & models Chairs: Kenji KABASHIMA, Martin STEINHOFF Standard session with free communications (01h30) |
| 08:30 | IL13 |
Keynote lecture: Reconsidering the farm effect in AD and allergyErika JENSEN-JAROLIM, Vienna |
| 08:50 | OL1 |
Acute stress aggravates itch in experimental atopic dermatitis and drives changes in trigeminal ganglion neurons related to neuroinflammationSang Eun LEE |
| 09:05 | OL2 |
Filaggrin insufficiency affects long-distant communication mediated by keratinocyte-derived small extracellular vesicles and promotes allergic inflammationDanuta GUTOWSKA-OWSIAK |
| 09:20 | OL3 |
The immune response of sensitzed AD patients to house dust mite comprises IL-17, capable of inducing a cytokine response from keratinocyesLennart M. ROESNER |
| 09:35 | OL4 |
Characterization of IL-13 producing cells in moderate to severe adult Atopic dermatitis patient’s skinGaurav ISOLA |
| 09:50 |
Q&A |
|
| 10:00 | Poster session 2 + 30 min Coffee break [details] | |
| 10:30 | 5. | Topical treatment and phototherapy: an endangered regimen? Chairs: Michael J. CORK, John C. SU Standard session with free communications (01h30) |
| 10:30 | IL14 |
Keynote lecture: The evolution of topical treatment of Atopic dermatitisAndreas WOLLENBERG, Munich |
| 10:50 | OL5 |
Association of cumulative topical corticosteroid exposure with fractures among older adults: a case-control studyAaron M. DRUCKER |
| 11:05 | OL6 |
Association between the use of topical calcineurin inhibitors and the risk of cancer among patients with atopic dermatitis: A nationwide, population-based, retrospective cohort studyChia-Yu CHU |
| 11:20 | OL7 |
Early relief of clinical symptoms and the improvement during the maintenance period of childhood atopic dermatitis: A multicenter clinical study of crisaborole ointmentShan WANG |
| 11:35 | OL8 |
The effectiveness of antibacterial therapeutic clothing compared with to non-antibacterial therapeutic clothing in patients with moderate to severe atopic dermatitis: preliminary results from a pragmatic randomized controlled trialAviël RAGAMIN |
| 11:50 |
Q&A |
|
| 12:00 | 6. | Global Corporate Pharma perspectives Chairs: Ncoza DLOVA, Peter SCHMID-GRENDELMEIER Scientific session programmed by corporate members (30 min.) |
Titles of communications to be announced |
||
| 12:30 | 7. | Highlighting new drugs in real life Chairs: Ncoza DLOVA, Alan D. IRVINE (30 min.) |
| 12:30 | OL11 |
Real-world data of abrocitinib treatment in patients with atopic dermatitis: results from the BioDay registryEsmé KAMPHUIS |
| 12:40 | OL12 |
Efficacy and safety of upadacitinib for atopic dermatitis in dupilumab non-responders: a multicenter retrospective studyJensen YEUNG |
| 12:50 | OL13 |
Baricitinib as a Useful Treatment for Mild-to-Moderate Atopic Dermatitis: A Real-World ExperienceNarang HONG |
| 13:00 | 60 min Lunch break | |
| 14:00 | 8. | AD comorbidities: facts, fancy, fiction Chairs: Magdalena CZARNECKA-OPERACZ, Mette DELEURAN (01h30) |
| 14:00 | IL15 |
Keynote lecture: AD comorbidities: the EBM of todayJiyoung AHN, Seoul |
| 14:20 | IL16 |
Coexistence of AD and alopecia areata. Impact on therapeutic decisionsLidia RUDNICKA, Warsaw |
| 14:35 | OL14 |
Atopic dermatitis is associated with increased risk of onset of cardiovascular diseases: a retrospective analysis based on electronic records from the global collaborative networkHenner ZIRPEL |
| 14:50 | OL15 |
Impact of COVID-19 and COVID-19 vaccination on atopic dermatitis patients: Lessons from the SECURE-AD Patient SurveyBouchra EZZAMOURI |
| 15:05 | OL16 |
Atopic Dermatitis as a Risk Factor for Post-arthroplasty Surgical Site Infections in Older AdultsYagmur HALEZEROGLU |
| 15:20 |
Q&A |
|
| 15:30 | Poster session 3 + 30 min Coffee break [details] | |
| 16:00 | 9. | Systemic strategies for children & adults Moderators: Amy S. PALLER, Thomas BIEBER (01h30) |
Short-term or long-term treatment? when & how to start? Early systemic intervention in children?Roundtable format, discussants: Michele RAMIEN, Carlo GELMETTI, Kenji KABASHIMA, Kyu Han KIM, John C. SU, Antonio TORRELO, Andreas WOLLENBERG |
||
| 17:30 | 10. | Travel grants and ISAD fellowships Chairs: Johannes RING, Jacek SZEPIETOWSKI Communications from grant awardees (01h00) |
| 17:30 | OL17 |
Major adverse cardiovascular events in patients treated with oral Janus kinase inhibitors for atopic dermatitis: a systematic review and meta-analysisCatherine DROITCOURT |
| 17:45 | OL18 |
The effect of single nucleotide polymorphism in COL23A1 gene on increased HSV-1 susceptibility of human macrophagesMikhail MAKMATOV-RYS |
| 18:00 | OL19 |
Quality of life in patients with atopic dermatitis in BamakoLamissa CISSE |
| 18:15 | OL20 |
The Dynamics of Skin Microbiome during Treatment in Patients with Atopic DermatitisAlpana MOHTA |
| 18:30 |
Q&A |
|
| 20:00 | Gala Dinner: Teatr Szekspirowski (Gdańsk Shakespeare Theatre) (03h00) | |
➜ Check details here |
||
Breakthroughs and challenges day
|
||
| 08:30 | 11. | Challenges in AD management Chairs: Małgorzata SOKOŁOWSKA-WOJDYŁO, Sébastien BARBAROT Standard session with free communications (01h30) |
| 08:30 | IL17 |
Keynote lecture: Treatment of AD in pregnancy and lactation periodChristian VESTERGAARD, Åarhus |
| 08:50 | IL18 |
Safety of atopic dermatitis therapies in the context of cutaneous lymphomas’ riskMałgorzata SOKOŁOWSKA-WOJDYŁO, Gdańsk |
| 09:05 | OL21 |
The concept of disease modification in atopic dermatitis: scientific and regulatory challenges for drug discovery and developmentThomas BIEBER |
| 09:20 | OL22 |
Treatment response to continuous Dupilumab over time: a retrospective observational study of 123 adult atopic dermatitis patients with changes in blood biomarkers for more than 2 yearsHaruna MATSUDA-HIROSE |
| 09:35 | OL23 |
Molecular profiling of allergen-antibody IgE and the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mitesMartyna MIODOŃSKA |
| 09:50 |
Q&A |
|
| 10:00 | Poster session 4 + 30 min Coffee break [details] | |
| 10:30 | 12. | Therapeutic and technology innovation 1 Chairs: Adam REICH, Thomas WERFEL Standard session with free communications (01h30) |
| 10:30 | IL19 |
Keynote lecture: Vaccination against allergiesMartin BACHMANN, Bern |
| 10:50 | OL24 |
The skin microbiome prior to the development of childhood atopic dermatitisAnne-Sofie HALLING |
| 11:05 | OL25 |
Dupilumab provides sustained effectiveness in patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice Bioday RegistryJunfen ZHANG |
| 11:20 | OL26 |
Real-Life Case-Series Experience with Tralokinumab in patients with severe atopic dermatitisFrancesca CAROPPO |
| 11:35 | OL27 |
In pursuit of meaningful change: enhancing interpretability of the Recap of atopic eczema (RECAP) instrumentArabella BAKER |
| 11:50 |
Q&A |
|
| 12:00 | 13. | Therapeutic and technology innovation 2 Chairs: Joanna NARBUTT, DirkJan HIJNEN Standard session with free communications (01h30) |
| 12:00 | IL20 |
Keynote lecture: Internet data mining and ADAlexander ZINK, Munich |
| 12:20 | OL28 |
A Large Language Model Artificial Intelligence for Patient Queries in Atopic DermatitisPranvera SULEJMANI |
| 12:35 | OL29 |
McGill Adult Atopic Dermatitis Digital Outcomes (MAADDO) Study: Development and User Testing of the EczemaQ Mobile ApplicationKaiyang LI |
| 12:50 | OL30 |
Real-World Experience on Efficacy and Safety of Upadacitinib in Patients with Atopic Dermaitits in KoreaJiyoung AHN |
| 13:05 | OL31 |
The Impact of Baseline Disease Severity on Short-Term Efficacy of Abrocitinib and Dupilumab in Patients With Atopic Dermatitis: A Post Hoc Analysis of the Phase 3 JADE COMPARE TrialZakiya P. RICE |
| 13:20 |
Q&A |
|
| 13:30 | Closing ceremony (30 min) | |
Closing remarksMagdalena TRZECIAK & Alain TAÏEB |
||
Next Rajka Symposium: Doha, QatarMartin STEINHOFF |
||
| 14:00 | Farewell lunch | |
Honour Patronages:
